Evidence map›Paper›PMID 39691713›Full record

ReviewFrontiers in immunology2024

Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease.

Sijia Yan, Xi Ming, Xiaojian Zhu, Yi Xiao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sijia Yan *Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Xi Ming *Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Xiaojian ZhuDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Yi XiaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic active Epstein-Barr Virus disease is a kind of Epstein-Barr Virus associated T/NK cell lymphoproliferative disease. At present, there is still a lack of standard therapeutic regimen for its treatment, but its basic treatment principles include controlling inflammatory response, anti-tumor proliferation, and immune reconstitution. Hematopoietic stem cell transplantation is currently the only method that can cure this disease. In recent years, immunotherapy has developed rapidly and is widely used in the treatment of various hematological malignancies; various immunotherapy drugs, including PD-1 inhibitors, have also demonstrated their safety and efficacy in CAEBV, while immune cell therapies such as Epstein- Barr virus-specific T cells have also displayed their unique advantages in CAEBV.

Indexed as

Epstein-Barr Virus InfectionsHerpesvirus 4, HumanImmunotherapyAnimalsChronic DiseaseHematopoietic Stem Cell TransplantationHumansImmune Checkpoint InhibitorsLymphoproliferative DisordersT-LymphocytesImmune Checkpoint Inhibitorschronic active Epstein-Barr virus diseaseEpstein-Barr virusEpstein-Barr virus specific cytotoxic T lymphocytesimmunotherapyPD-1 inhibitor

Identifiers

PMID39691713
PMCPMC11649625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.